SC
BMRN icon

SouthState Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

SouthState Corp’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$802 Sell
14
-15
-52% -$822 ﹤0.01% 1151
2026
Q1 		$1.64K Buy
29
+19
+190% +$1.11K ﹤0.01% 940
2025
Q4 		$595 Sell
10
-29
-74% -$1.58K ﹤0.01% 1208
2025
Q3 		$2.11K Sell
39
-15
-28% -$858 ﹤0.01% 926
2025
Q2 		$2.97K Sell
54
-52
-49% -$3.06K ﹤0.01% 1016
2025
Q1 		$7.49K Buy
+106
New +$7.13K ﹤0.01% 896

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SouthState Corp's BMRN Position: Q2 2026 in Review

SouthState Corp reduced its BioMarin Pharmaceuticals (BMRN) stake by 52% in Q2 2026, selling an estimated $822 and leaving 14 shares worth $802. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

SouthState Corp first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.49K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SouthState Corp held 14 shares of BioMarin Pharmaceuticals worth $802 as of Q2 2026.
  • SouthState Corp sold 15 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $822.
  • BioMarin Pharmaceuticals made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #1151 holding.
  • SouthState Corp first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • SouthState Corp's BioMarin Pharmaceuticals position peaked at $7.49K in Q1 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.